63E Stock Overview
A medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Onward Medical N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.76 |
| 52 Week High | €6.34 |
| 52 Week Low | €2.04 |
| Beta | 0.80 |
| 11 Month Change | -3.64% |
| 3 Month Change | 2.59% |
| 1 Year Change | 33.71% |
| 33 Year Change | -61.74% |
| 5 Year Change | n/a |
| Change since IPO | -62.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 63E | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.4% | 2.2% | 1.5% |
| 1Y | 33.7% | -4.2% | 8.8% |
Return vs Industry: 63E exceeded the German Medical Equipment industry which returned -4.2% over the past year.
Return vs Market: 63E exceeded the German Market which returned 8.8% over the past year.
Price Volatility
| 63E volatility | |
|---|---|
| 63E Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 63E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 63E's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 99 | Dave Marver | www.onwd.com |
Onward Medical N.V., a medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord. The company engages in developing ARCEX, a transcutaneous system designed to improve upper extremity strength, function, and other symptoms in people with spinal cord injury (SCI); ARCIM, a minimally invasive implantable system to address blood pressure instability and other symptoms in people with SCI; and ARCBCI, which adds an implantable bran-computer interface to the ARCIM to restore thought-driven movement of the upper and lower limbs. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Onward Medical N.V. Fundamentals Summary
| 63E fundamental statistics | |
|---|---|
| Market cap | €162.76m |
| Earnings (TTM) | -€35.15m |
| Revenue (TTM) | n/a |
-865.7x
P/S Ratio-4.6x
P/E RatioIs 63E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 63E income statement (TTM) | |
|---|---|
| Revenue | -€188.00k |
| Cost of Revenue | €13.44m |
| Gross Profit | -€13.63m |
| Other Expenses | €21.52m |
| Earnings | -€35.15m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 7,250.53% |
| Net Profit Margin | 18,697.34% |
| Debt/Equity Ratio | 87.3% |
How did 63E perform over the long term?
See historical performance and comparison